Background: The inhibitors of nuclear factor kappa-B kinase subunit epsilon (IKBKE) and TANK-binding kinase 1 (TBK1) are important members of the nonclassical IKK family that share the kinase domain. They are important oncogenes for activation of several signaling pathways in several tumors. This study aims to explore the expression of IKBKE and TBK1 and their prognostic role in stage I non-small cell lung cancer (NSCLC). Patients and methods: A total of 142 surgically resected stage I NSCLC patients were enrolled and immunohistochemistry of IKBKE and TBK1 was performed. Results: IKBKE and TBK1 were expressed in 121 (85.2%) and 114 (80.3%) of stage I NSCLC patients respectively. IKBKE expression was significantly associated with TBK1 expression (P=0.004). Furthermore, multivariate regression analyses showed there was a significant relationship between patients with risk factors, the recurrence pattern of metastasis and IKBKE+/TBK1+ co-expression (P=0.032 and P=0.022, respectively). In KaplanMeier survival curve analyses, the IKBKE+/TBK1+ co-expression subgroup was significantly associated with poor overall survival (P=0.014). Conclusions: This is the first study to investigate the relationship between IKBKE and TBK1 expression and clinicopathologic characteristics in stage I NSCLC patients. IKBKE +/TBK1+ co-expression was significantly obvious in patients with risk factors and with recurrence pattern of distant metastasis. Furthermore, IKBKE+/TBK1+ is also an effective prognostic predictor for poor overall survival.
Introduction
Lung cancer is the leading cause of cancer-related death worldwide. Non-small cell lung cancer(NSCLC) accounts for 80-85% of all lung cancer cases. 1, 2 The primary treatment for stage I NSCLC is surgical resection, but at least 30% of patients experienced recurrence within 5 years. 3 Adjuvant chemotherapy is recommended for patients with risk factors, such as poor histologic differentiation, vascular invasion, wedge resection, tumors >4 cm, incomplete lymph node sampling, and visceral pleural invasion. 4 Even after receiving adjuvant chemotherapy, the 5-year survival rate is only 60-90% due to local recurrence or distant metastasis. 5, 6 Therefore, we defined high-risk patients as tending to local recurrence or distant metastasis. It is challenging to screen true high-risk patients for adjuvant chemotherapy, and to avoid unnecessary adjuvant chemotherapy in low-risk patients to reduce the survival reduction caused by treatment-related toxicity. The IKK family contains five protein factors. IKKα, IKKβ, and IKKγ belong to canonical group, and the other two (IKBKE and TBK1) belong to non-canonical group. 7 The amino acid sequence analysis confirmed that IKBKE has 67% homology with TBK1. 8 IKBKE is highly expressed in human normal pancreatic tissue, thyroid tissue, spleen, and peripheral blood leukocytes, and can be up-regulated by multiple cytokines such as tumor necrosis factor alpha (TNF-α), IL-1, IL-6, and interferon-γ. 9 TBK1
is constitutively expressed in immune cells, brain, lungs, gastrointestinal tract, and reproductive organs. 10 Studies have demonstrated that IKBEK and TBK1 need to bind to scaffold proteins to form a protease complex to activate downstream protein factors, thereby activating the NF-κB pathway. TNAK (TNF receptor-associated factor family member-associated NF-κB activator), NAP1 (NAK associated protein 1), and SINTBAD (similar to NAP and TBK1 adaptor) are the main scaffold proteins. [11] [12] [13] [14] [15] [16] [17] Several studies have shown that IKBKE was overexpressed in breast cancer, glioma, gastric cancer, pancreatic cancer, ovarian cancer, renal cancer, and lung cancer and was associated with poor prognosis. [18] [19] [20] [21] [22] [23] [24] IKBKE and TBK1 may play important roles in tumorigenesis, proliferation, and angiogenesis. 25, 26 Nevertheless, the association between IKBKE and TBK1 expression and clinicopathological characteristics and its role in the prognosis of stage I NSCLC has not been reported. 
Patients and methods

Patient selection
Immunohistochemistry
Tumor tissue samples were obtained from 142 surgically resected stage I NSCLC patients. Surgically resected specimens were fixed in formalin and embedded in paraffin. Then, 4-μm paraffin-embedded sections were dewaxed and heated to 95°C for 20 mins for antigen retrieval in 10 mmol/L citrate buffer. Then, the sections were cleared of endogenous peroxidase activity and were blocked with 5% BSA for 30 mins in room temperature (RT). Then, all sections were incubated at 4°C overnight with primary anti-IKBKE (ab7891, Abcam, IHC 1:100, Cambridge, MA) or anti-TBK1 (ab109735, Abcam, IHC 1:400, Cambridge, MA). Then, the specimens were incubated with biotinylated secondary antibodies for 1 hr in RT. After incubation with ABC-peroxidase for 1 hr then all sections were colored using a DAB Kit (ZSGB-BIO, People's Republic of China) and counterstained with hematoxylin. All IHC results were evaluated by two pathologists. Double-blind readings were performed by two pathologists at the unknown tumor grade, and 10 fields were randomly collected from each pathological section, and the percentage of positive cells and the intensity of staining were scored: 1) coloring cells accounted for <5% cell count is 0; 5-25% is 1 point; 26-50% is 2 points; 51-75% is 3 points; and >75% is 4 points; 2) no staining is 0 points; the light yellow is 1 point; the brown and yellow is 2 points; the sepia is 3 points; 3) the two points are multiplied to form a positive grade: 0 is negative (-), 1-4 is weakly positive (+), 5-8 is positive (+ +), and 9-12 is strongly positive (+++).
Statistical analysis
The categorical variables were tested using Pearson's chisquared tests or Fisher's exact test, and continuous variables were expressed as means±SD and were analyzed using independent t-test. The significant (P<0.05) clinicopathological characteristics in univariate analysis were enrolled in multivariate logistic regression analysis, and multivariate logistic regression analysis was used to confirm the independent clinicopathological characteristics which were associated with IKBKE and TBK1 expression. The Kaplan-Meier was used to analyze progression-free survival (PFS) and OS, and the survival curves of four subgroups were compared by logrank test. All analysis was two-sided, and P<0.05 was considered statistically significant. Statistical analysis was performed using SPSS (version 20.0). (Table 2) .
Results
Expression
IKBKE and TBK1 co-expression in stage I NSCLC patients
We divided all patients into four subgroups according to IKBKE and TBK1 expression as follows: IKBKE-/TBK1-(n=9, 6.3%); IKBKE+/TBK1-(n=19, 13.4%); IKBKE-/ TBK1+ (n=12, 8.5%); IKBKE+/TBK1+ (n=102, 71.8%).
The representative examples of four subgroups are shown in Figure 1 . We then explored the association of IKBKE and TBK1 co-expression and clinicopathological characteristics (Table 3) . Patients with risk factors and patients with the recurrence pattern of metastasis had more frequency in the IKBKE+/TBK1+ subgroup than in other three subgroups (P=0.042 and P=0.004, respectively). In addition, we did not find significant association between other clinicopathological characteristics and the expression of IKBKE and TBK1. In multivariate regression analysis of clinicopathological characteristics for IKBKE and TBK1 co-expression, we found patients with risk factors and the recurrence pattern of metastasis were significantly related to IKBKE+/TBK1+ co-expression (P=0.032 and P=0.022, respectively). Figure 2 ).
Discussion
Our study tried to investigate IKBKE and TBK1 expression in stage I NSCLC and the association between their expression and clinicopathological characteristics. We found that IKBKE and TBK1 expressed in 85.2% and 80.3% of stage I NSCLC, respectively, and IKBKE and TBK1 co-expressed in 71.8% of all cases. Identifying high-risk patients who need postoperative adjuvant chemotherapy to improve OS and reduce the toxicity of unnecessary chemotherapy is a key element in the whole treatment management of early-stage NSCLC. Our study demonstrated that IKBKE and TBK1 might play an important role in tumorigenesis and proliferation in stage I NSCLC. IKBKE and TBK1 may be good molecular targets for combination therapy. Targeted therapy is the treatment of precise targeting molecular "targets" by small molecule drugs that specifically bind to these targets. Protein kinases are important signal messengers to modulate cell life activities and play an important role in cell proliferation, survival, apoptosis, metabolism, transcription, and differentiation. IKBKE and inhibit the proliferation of NSCLC lines in vitro, block the development and progression of NSCLC induced by IKBKE and TBK1 mediated KRAS-driven tumorigenesis. 39 Considering the high positive expression rate of IKBKE and TBK1 in stage I NSCLC, targeted therapy targeting IKBKE and TBK1 might be a potential strategy to suppress cancer development.
In our study, we explored the correlation between the following clinicopathological characteristics, including gender, age, differentiation, histologic type, risk factors, and recurrence pattern and IKBKE/TBK1 expression status. We found IKBKE+/TBK1+ expressed in 71.8% of all cases, suggesting that IKBKE and TBK1 may play a pivotal role in NSCLC initiation. The multivariate regression analysis was applied to select prediction characteristics for IKBKE+/TBK+ expression in stage I NSCLC and the multivariate analysis demonstrated patients with risk factors and the recurrence pattern of metastasis were significantly related to IKBKE +/TBK1+ co-expression (P=0.032 and P=0.022, respectively).
In addition, we did not find significant association between other clinicopathological characteristics and the expression of IKBKE and TBK1. The stage I NSCLC patients with risk factors were optimal candidates to receive adjuvant chemotherapy, whereas the locoregional or systemic recurrence was still high in these patients. 5 Even in stage I NSCLC patients with no risk factors, the locoregional or systemic recurrence also could not be ignored. Therefore, how to explore effective treatments to prolong the OS time in high-risk patients remains challenging. Our research provides a new perspective for screening high-risk patients. We found stage I NSCLC patients with risk factors were significantly related to IKBKE+/TBK1+ co-expression (P=0.032). Furthermore, we found the recurrence pattern of metastasis was also significantly related to IKBKE+/TBK1+ co-expression (P=0.022). Recently, studies have shown IKBKE and TBK1 could phosphorylate AKT to activate AKT pathway, 30, 40 and AKT1
regulates pathological angiogenesis, vascular maturation, and permeability. 41 All these may explain why the patients with IKBKE+/TBK1+ co-expression were prone to recurrence with metastasis in our study and the IKBKE+/TBK1+ subgroup has shorter OS than other subgroups (P=0.014), whereas we did not find statistically significant PFS differences between the four subgroups (P=0.109). Li et al showed IKBKE Groups   IKBKE-TBK1-IKBKE+TBK1-IKBKE+TBK1+  IKBKE+TBK1+  IKBKE-TBK1-IKBKE+TBK1-IKBKE+TBK1+  IKBKE+TBK1+   Groups   IKBKE-TBK1-IKBKE+TBK1-IKBKE-TBK1+  IKBKE+TBK1+  IKBKE-TBK1-IKBKE+TBK1-IKBKE- demonstrated that TBK1 contributes to tumor invasion and might be a driving factor for metastatic spread of breast cancer. Thus, IKBKE/TBK1 dual inhibitors combined with adjuvant chemotherapy may be a potential strategy for high-risk stage I NSCLC patients. Apparently, our study has several limitations that should be considered. The retrospective character of this study exists inevitable bias. Considering the limited amount of tissue, we cannot test as many as possible relevant proteins. Moreover, when the patient relapsed, we were unable to obtain the specimen, but only analyzed the specimen that was surgically removed at the initial diagnosis, which limited our understanding of the changes in tumor molecular characteristics.
In conclusion, the current study provides further insights for tumor targeted therapy and the landscape of kinase proteins IKBKE and TBK1 in various cancers. To our knowledge, our study is the first study to investigate the relationships between expression of IKBKE and TBK1 and clinicopathologic characteristics in stage I NSCLC patients and their predictive significance on patients' survival. We found IKBKE+/TBK1+ co-expression was significantly obvious in patients with risk factors and the recurrence pattern of metastasis, and is an effective prognostic predictor for poor OS. Of note, further investigation is required to identify optimal patients who likely obtain benefit from IKBKE and TBK1 dual inhibitors therapy.
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